NARA Discovery
Article Details
← Back to Search Results
Journal Article

Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products

Robert Price; Jagdeep Shur; William Ganley; Gonçalo Farias; Nikoletta Fotaki; Denise S. Conti; Renishkumar Delvadia; Mohammad Absar; Bhawana Saluja; Sau Lee
The AAPS Journal · Vol. 22, Issue 2 · 2020

Abstract

The aim of the study was to develop a robust and standardized in vitro dissolution methodology for orally inhaled drug products (OIDPs). An aerosol dose collection (ADC) system was designed to uniformly deposit the whole impactor stage mass (ISM) over a large filter area for dissolution testing. All dissolution tests were performed under sink conditions in a sodium phosphate buffered saline solution containing 0.2% w /w sodium dodecyl sulphate. An adapted USP Apparatus V, Paddle over Disk (POD), was used throughout the study. The dissolution characteristics of the ISM dose of a commercial metered-dose inhaler (MDI) and a range of dry powder inhaler (DPI) formulations containing inhaled corticosteroids were tested. The uniform distribution of the validated ISM dose considerably reduced drug loading effects on the dissolution profiles for both MDI and DPI formulations. The improvement in the robustness and discriminatory capability of the technique enabled characterization of dissolution rate differences between inhaler platforms and between different DPI product strengths containing fluticasone propionate. A good correlation between in vivo mean absorption time and in vitro dissolution half-life was found for a range of the inhaled corticosteroids. The ADC system and the reproducible in vitro POD dissolution measurements provided a quantitative-based approach for measuring the relationship between the influence of device and the dispersion characteristics on the aerosol dissolution of low solubility compounds. The in vitro dissolution method could potentially be applied as a dissolution methodology for compendial, quality control release testing, and during development of both branded orally inhaled drug products and their generic counterparts.

Bibliographic Information

JournalThe AAPS Journal
PublisherSpringer
Publication Date2020-03-01
Publication Year2020
Volume22
Issue2
Document TypeJournal Article
eISSN1550-7416
DOI10.1208/s12248-020-0422-y

Access Information

NARA Access Coverage1999-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12248
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.